PLRZHealthcare · Biotechnology

PLRZ Stock Forecast: Polyrizon Ltd. Price Predictions for 2026-2027

Last close, 7 Oct 2026

$9.15

−5.38% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 6 Oct 2026 — in the weakest quartile.

Market cap

$23.5M

Ticker Nerd rank

16 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−15.1%

−18.6%

YTD

+7.8%

+4.0%

From 52W high

−46.7%

From 52W low

+192.1%

$17

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

PLRZ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Polyrizon Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026

16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Momentum

Volatility

Growth

Revisions

Issuance

Accruals

Quality

Value

Size (87): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PLRZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLRZ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLRZ appears on the weeks it earns a place.

Performance

PLRZ vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Polyrizon Ltd. returned +4.0% against +17.7% for the S&P 500, dividends included.

PLRZ vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PLRZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Polyrizon Ltd. (PLRZ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: —
Price / book: 0.8×
EV / EBITDA: −0.5×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −21.4%
Return on assets: −23.3%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Polyrizon Ltd. (PLRZ) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Polyrizon Ltd. has a market value of $23.5M and an enterprise value of $3.6M.
Shares outstanding: 1.6M.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Polyrizon Ltd. employs 2 people.

market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

PLRZ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
PLRZPolyrizon Ltd.	$23.5M	16
KYNBKyntra Bio, Inc.	$24.1M	42
ATOSAtossa Therapeutics, Inc.	$24.4M	25
COCPCocrystal Pharma, Inc.	$21.4M	67
QNTMQuantum BioPharma Ltd.	$25.0M	50
ABVCABVC BioPharma, Inc.	$25.9M	12
NXTCNextCure, Inc.	$26.0M	78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Polyrizon Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PLRZ news & analysis

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

GlobeNewsWire · 5 Oct 2026positive

Polyrizon has filed a new U.S. patent application covering its proprietary mucoadhesive platform and its potential applications in intranasal drug delivery. The filing is intended to expand the company's intellectual property moat around its drug-delivery technology.

Why it matters — PLRZ watchers would care because a broader patent portfolio could strengthen the company's competitive position and protections for its intranasal drug-delivery platform.

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker

GlobeNewsWire · 22 Sept 2026positive

Polyrizon has enrolled its first patient in a U.S. clinical study of its NASARIX (PL-14) Allergy Blocker, which is designed to evaluate the efficacy, safety and tolerability of the product in patients with seasonal allergic rhinitis. This marks the company's transition into a clinical-stage company.

Why it matters — A PLRZ watcher would care because this milestone advances the company from a pre-clinical to a clinical-stage developer, moving its lead allergy product closer to potential regulatory validation.

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

GlobeNewsWire · 4 Sept 2026neutral

Polyrizon Ltd. announced the closing of a $4.0 million registered direct offering and private placement. The company, headquartered in Raanana, Israel, made the announcement on September 4, 2026.

Why it matters — The closing of this offering indicates the company has secured new capital, which PLRZ watchers would track as a liquidity and financing event.

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

GlobeNewsWire · 3 Sept 2026neutral

Polyrizon Ltd. announced it has entered into definitive agreements with a single institutional investor for a registered direct offering of its Ordinary Shares and pre-funded warrants, along with a concurrent private placement of pre-funded and investor warrants. Aggregate gross proceeds from both transactions are expected to be approximately $4.0 million.

Why it matters — This capital raise provides Polyrizon with funding for its development-stage intranasal hydrogel programs.

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

GlobeNewsWire · 2 Sept 2026positive

Polyrizon announced it has completed contracting with the fourth and fifth clinical sites participating in its U.S. clinical study of NASARIX™ Allergy Blocker (PL-14), thereby completing all five site contracts for the first-in-human allergy study.

Why it matters — This milestone means all required U.S. clinical sites for the NASARIX first-in-human allergy study are now contracted, moving the development-stage biotech closer to initiating its trial.

FAQ

Frequently asked questions about PLRZ stock

How does Ticker Nerd's model rank PLRZ?

As at 6 Oct 2026, Polyrizon Ltd. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

What is the PLRZ stock forecast for 2030?

No analyst covering Polyrizon Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLRZ are extrapolating price history, which says nothing about the business.

How has PLRZ stock performed over the past year?

Polyrizon Ltd. returned +4.0% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Polyrizon Ltd. do?

Polyrizon Ltd. is an Israel-based biotechnology company focused on developing innovative intranasal protective products.

What is the latest news on PLRZ?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform". Polyrizon has filed a new U.S. patent application covering its proprietary mucoadhesive platform and its potential applications in intranasal drug delivery. The filing is intended to expand the company's intellectual property moat around its drug-delivery technology.

Company

About Polyrizon Ltd.

Polyrizon Ltd. is an Israel-based biotechnology company focused on developing innovative intranasal protective products. The company specializes in medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity, designed to help prevent viruses, allergens, and other airborne particles from contacting nasal tissue. Its proprietary Capture and Contain technology is intended to create a temporary shield in the nose, while its Trap and Target platform supports intranasal delivery of active pharmaceutical ingredients. Polyrizon also develops product candidates aimed at nasal allergy blocking and influenza protection. In addition to preventative intranasal solutions, the company works on improving bioadhesion and retention characteristics for drug delivery applications. Polyrizon Ltd. serves the healthcare and biotechnology markets through research, development, and commercialization of nasal-care technologies.

CEO Mr. Tomer Izraeli · 2 employees · Israel · https://www.polyrizon-biotech.com